Compare ODC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | URGN |
|---|---|---|
| Founded | 1941 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 995.6M | 922.1M |
| IPO Year | 1994 | 2016 |
| Metric | ODC | URGN |
|---|---|---|
| Price | $61.55 | $18.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 60.2K | ★ 803.1K |
| Earning Date | 06-19-2026 | 06-10-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $1,128,000.00 |
| Revenue This Year | N/A | $119.37 |
| Revenue Next Year | N/A | $64.79 |
| P/E Ratio | $36.75 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $41.37 | $3.42 |
| 52 Week High | $70.01 | $30.00 |
| Indicator | ODC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 40.14 |
| Support Level | $60.61 | $16.47 |
| Resistance Level | $63.41 | $20.44 |
| Average True Range (ATR) | 2.78 | 1.40 |
| MACD | -0.81 | -0.15 |
| Stochastic Oscillator | 9.35 | 13.79 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.